Drug development pulmonary diseasesMpex, USA
Mpex was acquired by Axcan in 2011.
Diagnostics cervical cancermtm Laboratories, Germany
mtm was acquired by Roche for up to EUR190 million in 2011.
Drug development antibacterialsNabriva, Austria
Nabriva was listed on NASDAQ in 2015.
Drug development neurologyNewron Pharmaceuticals, Italy
Newron was listed on SIX Swiss Exchange in 2006.
Medical device neurologyNorthstar Neurosciences, USA
Northstar was listed on NASDAQ in 2006.
Women’s HealthObsEva, USA / Switzerland
ObsEva was listed on NASDAQ in 2017.
Drug development ophthalmologyOphthotech, USA
Ophthotech was listed on NASDAQ in 2013.
Molecular biology platformPanomics, USA
Panomics was acquired by Affymetrix for $73 million in 2008.
Drug development antibacterialsParatek Pharmaceuticals, USA
Paratek was listed on NASDAQ in 2014.
Specialty pharmaPharmaSwiss, Switzerland
PharmaSwiss was acquired by Valeant for EUR350 million in 2009.
Medical device surgical instrumentsPrecimed, Switzerland/USA
Precimed was acquired by GreatBatch for $125 million in 2008.
OncologyPrincipia Biopharma, USA
Principia was listed on NASDAQ in 2018, then acquired by Sanofi for $3.7 billion in 2020.
Drug development alzheimerProbiodrug, Germany
Probiodrug was listed on Euronext in 2014.
Drug development orphan diseasesPTC
PTC was listed on NASDAQ in 2013.
Drug development neurologyRenovis, USA
Renovis was listed on NASDAQ in 2003.
Proteomic analysisSeer Therapeutics, USA
Seer was listed on NASDAQ in 2020.
Pharmaceutical packagingShriji Polymers Ltd
Secondary stake acquired by Creador Capital in 2020.
Drug development respiratory diseasesSkyePharma, U.K.
Merger with Vectura Group plc (LSE: VEC) in 2016.
DNA technology platformSloning BioTechnology, Germany
Sloning was acquired by Morphosys in 2010.
Drug developmentSublimity Therapeutics
Drug development oncologySunesis Pharmaceuticals, USA
Sunesis was listed on NASDAQ in 2005.
Drug development women's healthSymbiomix Therapeutics, USA
Symbiomix was acquired by Lupin for $150 million plus contingent payments in 2017.
Drug development rare blood diseasesSyntonix, USA
Syntonix was acquired by Biogen Idec for up to $120 million in 2007.
Drug discoverySyrrx, USA
Syrrx was acquired by Takeda for $270 million in 2005.
Medical device cardiovascularTandemLife (CardiacAssist), USA
TandemLife was acquired by LivaNova (Nasdaq:LIVN) for up to $250 million in 2018.
Patient monitoringTensys, USA
Assets of Tensys were acquired by a Chinese Company by end of 2017.
Drug discoveryTransform Pharmaceuticals, USA
Transform was acquired by Johnson & Johnson for $230 million in 2005.
Drug development rare blood diseasesTrue North Therapeutics, USA
True North Therapeutics was acquired by Bioverativ in 2017 for up to $825 million.
Cancer targeted therapiesTurning Point Therapeutics
Turning Point was acquired by Bristol Myers Squibb for $4.1 billion in 2022.
Autoimmune and severe inflammationViela Bio
Viela Bio was acquired by Horizon Therapeutics for $3 billion in 2021.
Drug development immunologyVitaeris Inc., Canada
Vitaeris was acquired by CSL Behring in 2020.
Anesthesia and respiratory productsWestmed, USA
Westmed was acquired by a subsidiary of Sunmed Group Holdings LLC for approximately $75 million in 2020.
Drug development neurologyXenoport, USA
Xenoport was listed on NASDAQ in 2005.
Medical device ophthalmologyZiemer, Switzerland
Sale of position to an investor in 2009.
Drug development antiviralsZycos, USA
Zycos was acquired by MGI Pharma for $50 million in 2004.